Record Q1 Net Revenue of $177 Million, Representing 15% Growth Year over Year Increased #1

22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage

BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage

CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report

LianBio to receive total upfront consideration of $350 millionLianBio Board of Directors to conduct strategic

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023

First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q

SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular

– Both EYP-1901 cohorts demonstrated a statistically non-inferior change in BCVA versus aflibercept control

Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week

Da Vinci 5 builds on decades of Intuitive technology and millions of robotic procedures......

– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally

AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR